New immune cell therapy for anaplastic thyroid cancer
Part of Cancer, Immune system & allergy clinical trials.
This study tests a new treatment combining NKG2D CAR-NK cells (a type of immune cell) with a PD-1 antibody (a drug that helps immune cells fight cancer) for people with anaplastic thyroid cancer, a rare and aggressive cancer. The goal is to see if this combo can shrink tumors and improve outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have been diagnosed with anaplastic thyroid cancer (a rare and fast-growing thyroid cancer).
- You have at least one tumor that is 1 cm or larger and can be seen on scans.
- Your liver and kidneys are working well enough to handle treatment.
- You do not have other serious health problems like immune, blood, lung, or mental health diseases, or another cancer.
- You are not pregnant, breastfeeding, or planning to have children soon.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study is comparing two different ways of giving radiation therapy for anaplastic and poorly differentiated thyroid cancer. The goal is to see which method is more effective in treating the cancer.
This early-stage study tests an experimental treatment that uses engineered immune cells (called CAR natural killer cells) to calm overactive immune responses in people with moderate to severe autoimmune diseases that have not fully responded to standard treatments. It aims to offer a new option for patients who have not gotten enough benefit from usual therapies.
This trial tests a new treatment using immune cells (CAR-NK) made from donated cord blood. These cells are designed to find and attack T-cell lymphoma that has come back or not responded to other treatments. The goal is to see if this approach is safe and effective.
This trial tests a new type of immune cell therapy (CAR-NKT) that targets a protein called CD70 on cancer cells. It is for people with advanced solid tumors that have not responded to at least two prior treatments and whose tumors are CD70-positive.
This trial tests a combination of two drugs (sinibolimab and lenvatinib) given before surgery. The goal is to shrink advanced thyroid cancer that cannot be fully removed otherwise, so that surgery can be more successful.
This trial tests a combination of two drugs—donafenib (a targeted therapy) and an immunotherapy (anti-PD-1 antibody)—given before surgery for locally advanced differentiated thyroid cancer. The goal is to shrink the tumor to make surgery easier and more complete. If you have this type of thyroid cancer that is hard to remove completely with surgery alone, this study may be an option.
Hear when a new Anaplastic Throid Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.